Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Pancreatic Adenocarcinoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Esophageal Neoplasms 1Endometrial Neoplasms 1Chordoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Liver Cancers 1

Interventions

Sorafenib 26Nivolumab 21pembrolizumab 15Bevacizumab 14lenvatinib 12atezolizumab 9Cyclophosphamide 9Ipilimumab 8durvalumab 6camrelizumab 5apatinib 5Specimen Handling 5Radiosurgery 5tislelizumab 4fludarabine 4Immunotherapy, Adoptive 4Fluorouracil 4Doxorubicin 4tremelimumab 3toripalimab 3sintilimab 3regorafenib 3cabozantinib 3X-Rays 3Magnetic Resonance Spectroscopy 3Injections 3Everolimus 3Ethiodized Oil 3Erlotinib Hydrochloride 3tepotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Hepatocellular × Tiragolumab × Clear all
NCT05908786 2025-12-11

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Hoffmann-La Roche

Phase 1/2 Completed
62 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡